证券之星消息，1月28日生物制品板块较上一交易日下跌1.98%，百普赛斯领跌。当日上证指数报收于 4151.24，上涨0.27%。深证成指报收于14342.9，上涨0.09%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301080 | 百普赛斯 | 58.18 | -10.57% | 5.74万 | 3.42亿 | | 920575 | 康乐卫士 | 10.97 | -6.16% | 12.07万 | 1.36亿 | | 688137 | 近岸蛋白 | 46.58 | -5.90% | 2.88万 | 1.36亿 | | 6168889 | 欧林生物 | 24.88 | -5.51% | 7.81万 | 1.97亿 | | 000518 | *ST四环 | 2.63 | -5.05% | 19.04万 | 5010.80万 | | 300318 | 博晖创新 | 7.27 | -4.97% | 64.60万 | 4.78亿 | | 301207 | 华兰婷曲 ...

证券日报网讯1月26日，安科生物（300009）在互动平台回答投资者提问时表示，公司参股公司博生吉 公司创新药物的海外授权工作持续推进中，若有结果公司会通过合适的方式进行披露。公司持续关注包 括以AI平台技术为核心技术的相关公司。隆培促生长激素即将结束国家CDE的审评。 ...

Group 1 - The core point of the article is that Anke Bio has received the "High-tech Enterprise Certificate" from multiple government bodies in Anhui Province, which may enhance its market position and credibility in the industry [2] Group 2 - Anke Bio's wholly-owned subsidiary, Anhui Anke Hengyi Pharmaceutical Co., Ltd., is the entity that received the certification [2] - The certificate was jointly issued by the Anhui Provincial Department of Industry and Information Technology, the Anhui Provincial Department of Finance, and the State Taxation Administration of Anhui Province [2]

Core Viewpoint - Anke Bio (300009.SZ) has received a new High-tech Enterprise Certificate from the Anhui Provincial Department of Industry and Information Technology, Anhui Provincial Department of Finance, and the State Taxation Administration of Anhui Province for its wholly-owned subsidiary, Anhui Anke Hengyi Pharmaceutical Co., Ltd. This certification is a renewal following the expiration of the previous certificate [1]. Group 1 - Anke Hengyi has been recognized as a high-tech enterprise, which may enhance its credibility and competitive position in the pharmaceutical industry [1]. - The renewal of the high-tech enterprise certification indicates ongoing compliance with the standards set by the relevant authorities, reflecting the company's commitment to innovation and technology [1].

证券代码：300009 证券简称：安科生物 公告编号：2026-002 安徽安科生物工程（集团）股份有限公司 关于全资子公司通过高新技术企业认定的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 安徽安科生物工程（集团）股份有限公司（以下简称"公司"）全资子公司 安徽安科恒益药业有限公司（以下简称"安科恒益"）于近日收到安徽省工业和 信息化厅、安徽省财政厅、国家税务总局安徽省税务局联合颁发的《高新技术企 业证书》，具体情况如下： 企业名称：安徽安科恒益药业有限公司 证书编号：GR202534002648 发证日期：2025 年 10 月 28 日 有效期：三年 本次高新技术企业认定系安科恒益原证书有效期满后进行的重新认定。根据 《中华人民共和国企业所得税法》等相关规定，安科恒益自通过高新技术企业认 定当年起，连续三年（2025 年至 2027 年）可继续享受国家关于高新技术企业的 相关税收优惠政策，即按 15%的税率缴纳企业所得税。安科恒益 2025 年度已按 照 15%的企业所得税税率进行纳税申报及预缴，本次通过高新技术企业认定事项 不会对公司 2025 年 ...

Group 1 - The core point of the article is that Anke Bio (300009) has responded to investor inquiries, indicating that the total number of shareholders is expected to reach 72,023 by December 31, 2025 [1]

证券代码：300009 证券简称：安科生物 公告编号：2026-001 安徽安科生物工程（集团）股份有限公司 关于部分限制性股票回购注销完成的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 特别提示： 1、安徽安科生物工程（集团）股份有限公司（以下简称"公司"）本次回购 注销限制性股票涉及激励对象人数 104 名；回购注销的限制性股票数量为 1,200,550 股，占回购注销前公司总股本 1,672,521,258 股的 0.0718%，其中：首 次授予限制性股票回购数量为 204,400 股，预留授予限制性股票回购数量为 996,150 股。 2、本次完成回购注销的限制性股票为公司第三期限制性股票激励计划（以 下简称"第三期激励计划"）授予的部分限制性股票，回购价格为授予价格，其 中首次授予部分回购价格为 4.81 元/股，预留授予部分回购价格为 5.27 元/股。本 次回购金额合计 6,232,874.50 元人民币，均为公司自有资金。 3、截至本公告披露日，公司已在中国证券登记结算有限责任公司深圳分公 司完成上述限制性股票回购注销手续。本次回购注销完成 ...

Core Viewpoint - Anke Bio (300009) reported a significant increase in sales revenue for its injectable trastuzumab "Ansaiting," projecting a year-on-year growth of 298% in the first half of 2025 [1] Group 1 - The company anticipates a substantial rise in sales revenue for its product, indicating strong market demand and potential growth opportunities [1]

Core Viewpoint - Anhui Anke Biotechnology (Group) Co., Ltd. is set to experience a peak in new drug launches in 2026, with a dual focus on self-developed innovative drugs and agency-represented blockbuster products, covering key therapeutic areas such as oncology, rare diseases, and assisted reproduction, which will reshape the company's performance growth pattern [1] Group 1: Self-Developed Drugs - The long-acting growth hormone pipeline is expanding, with the collaboration with Weisheng Pharmaceutical on Longpei Growth Hormone entering the production review stage, expected to launch between late 2025 and early 2026, significantly improving patient compliance with a once-weekly dosing frequency [1] - Two major self-developed products are anticipated to achieve market breakthroughs in 2026: PA3-17 injection, a CD7 CAR-T therapy for T-lymphoblastic leukemia/lymphoma, is included in the CDE's breakthrough therapy category, with a pivotal Phase II trial starting in October 2025 and a conditional market application expected around 2026 [2] - An anti-VEGF humanized monoclonal antibody has completed Phase III clinical trials and plans to submit for market approval in 2026, providing an important treatment option for advanced malignant tumors [2] - The HER2-targeted innovative drug HuA21 injection has completed Phase Ib/II clinical trials and aims to advance to Phase III clinical application in 2026, potentially overcoming existing treatment resistance in HER2-positive breast cancer [2] Group 2: Agency-Represented Drugs - The long-acting follicle-stimulating hormone "Shengnuo" is highlighted as China's first approved long-acting follicle-stimulating hormone injection, developed through a collaboration between Anke Biotechnology and Baoji Pharmaceutical, achieving a convenient "one injection covers one week" treatment [3] - Phase III clinical trials show that key indicators such as the number of eggs retrieved and live birth rates are comparable to short-acting formulations, with the average injection frequency reduced to 2.6 times [3] - A dedicated promotion team of 300 has been established, with expectations for significant revenue contributions in 2026, filling a market gap in the domestic long-acting follicle-stimulating hormone sector, which has a market size exceeding 6 billion yuan [3] Group 3: Overall Impact - Anke Biotechnology's robust positioning in growth hormones, anti-tumor, and assisted reproduction fields has established a dual product matrix of "self-developed + agency" [3] - The concentrated launch of multiple new drugs in 2026 is expected to enrich clinical treatment options, enhance the accessibility of domestic drugs, and potentially drive the company's performance to achieve exponential growth, solidifying its core competitiveness in the biopharmaceutical niche [3]

Group 1 - The Anhui Provincial Health Commission and other authorities have released the first batch of "new quality drug and medical device" product catalog to accelerate the promotion and application of innovative medical products, fostering new productive forces in the biopharmaceutical industry [1] - A total of 60 "new quality drug and medical device" products were announced, with 45 products from Hefei, accounting for 75% of the total in the province, highlighting Hefei's strong innovation capabilities and industrial clustering effect [1] - In the biopharmaceutical sector, all three selected biopharmaceuticals in the province are from Hefei, including innovative drugs for tuberculosis/influenza prevention by Zhifei Longcom and anti-tumor drugs by Anke Bio [1] Group 2 - Hefei's Industrial and Information Technology Bureau is actively promoting the innovative development of the biopharmaceutical industry, focusing on building a collaborative industrial ecosystem involving government, industry, academia, research, application, and finance [2] - The city is nurturing local leading enterprises such as Anke Bio, Opcon Vision, and Meiya Optoelectronics while successfully attracting innovative companies like Ruisi Digital Technology through high-level platforms [2] - Collaboration with institutions like the University of Science and Technology of China and Anhui University of Traditional Chinese Medicine has led to the incubation of technology-based SMEs, creating a favorable development pattern for large, medium, and small enterprises [2]